Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Due to the biological heterogeneity, 60%–70% of patients with major depressive disorder (MDD) do not respond to or achieve remission from first‐line antidepressants. Predicting neuroimaging biomarkers for early antidepressant treatment could guide initial antidepressant therapy.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Purpose</h3><p>To assess for neuroimaging biomarkers for antidepressant selection in early antidepressant treatment.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Study Type</h3><p>Prospective.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Subjects</h3><p>A total of 85 MDD patients from the major site and 33 MDD patients from an out‐of‐sample test site.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Field Strength/Sequence</h3><p>A 3.0 T, T1‐weighted imaging using a magnetization‐prepared rapid acquisition gradient‐echo sequence and diffusion tensor imaging (DTI) using an echo‐planar sequence.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Assessment</h3><p>Baseline DTI data of patients who achieved early improvement after 2‐weeks of antidepressant treatment (selective serotonin reuptake inhibitors [SSRI] or serotonin‐norepinephrine reuptake inhibitors [SNRI]) were analyzed. An ensemble model was constructed using data from the major site and then applied to assess the early response of patients at the out‐of‐sample test site.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Statistical Tests</h3><p>Support vector machine combined with leave‐one‐out cross‐validation were applied to construct the whole model from individual base models from different brain regions. Discriminative biomarkers were evaluated by calculating the changes in sensitivity and specificity obtained when removing a single base model from the whole model, the base model being removed changing in each run.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Training performance over MDD patients at the major site achieved 75% accuracy while performance with accuracy of 70% was achieved in the out‐of‐sample test site. Assessing sensitivity and specificity changes following the removal of single base models from the prominent model highlighted the functions of two neural circuitries: SSRI‐related emotion regulation circuitry, centered on the hippocampus (sensitivity changes: 10%) and amygdala (sensitivity changes: 11%); and SNRI‐related emotion and reward circuitry, centered on the putamen (specificity changes: 8%) and orbital part of superior frontal gyrus (specificity changes: 12%).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Data Conclusion</h3><p>These findings support future research on clinical antidepressant selection for MDD.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Evidence Level</h3><p>1</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Technical Efficacy</h3><p>Stage 2</p></section>

Abnormal Hippocampal Subfields May Be Potential Predictors of Worse Early Response to Antidepressant Treatment in Drug‐Naïve Patients with Major Depressive Disorder

Altered Hippocampal Subfield Volumes in Major Depressive Disorder with and Without Anhedonia.

Hippocampal and parahippocampal volume and function predict antidepressant response in patients with major depression: A multimodal neuroimaging study

Association Between Hippocampal Subfields and Clinical Symptoms of First-Episode and Drug Naive Schizophrenia Patients During 12 Weeks of Risperidone Treatment

Sub-hubs of Baseline Functional Brain Networks Are Related to Early Improvement Following Two-Week Pharmacological Therapy for Major Depressive Disorder.

The association between gray matter volume in the hippocampal subfield and antidepressant efficacy mediated by abnormal dynamic functional connectivity

Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder

Predicting individual responses to the electroconvulsive therapy with hippocampal subfield volumes in major depression disorder

Abnormal Dynamic Functional Connectivity of the Left Rostral Hippocampus in Predicting Antidepressant Efficacy in Major Depressive Disorder

Hippocampal subfield morphology from first episodes of bipolar disorder type II and major depressive disorder in a drug naïve Chinese cohort

Distinct Atrophy Pattern of Hippocampal Subfields in Patients with Progressive and Stable Mild Cognitive Impairment: A Longitudinal MRI Study

Predicting Neuroimaging Biomarkers for Antidepressant Selection in Early Treatment of Depression

Changes of brain morphometry in first-episode, drug-naïve, non-late-life adult patients with major depression: an optimized voxel-based morphometry study.

Volume of hippocampus-amygdala transition area predicts outcomes of electroconvulsive therapy in major depressive disorder: high accuracy validated in two independent cohorts

Brain Grey Matter Volume Alterations Associated with Antidepressant Response in Major Depressive Disorder.

Cortical Thickness Predicts Response Following 2 Weeks of SSRI Regimen in First-Episode, Drug-Naive Major Depressive Disorder: An MRI Study

Study on Functional Connectivity Between the Subgenual Anterior Cingulate Cortes and Limbic Cortices in Predicting the Efficacy of Early Antidepressant Treatment Outcome

Local and large-scale resting-state oscillatory dysfunctions for early antidepressant response prediction in major depressive disorder

Brain ventricle and choroid plexus morphology as predictor of treatment response in major depression: Findings from the EMBARC study

Volumetric Deficit Within the Fronto-Limbic-Striatal Circuit in First-Episode Drug Naïve Patients With Major Depression Disorder

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex